
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class…
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
Orakl Oncology works on a large cohort of patient-derived organoids (PDO) to predict clinical outcomes of patients and derisk clinical trials. We are looking for a dynamic and motivated Lab Technician to help us scale our cell culture and experimental platforms. In this position, you will:
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
65,000+
Open Roles
1,300+
New This Week
| Company |
|---|
In addition, this position is an amazing fit if you have: